EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia

Dan Wang, Jing He, Siyang Liu, Haixia Zhang, Daolin Tang, Pan Chen, Minghua Yang

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.216970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Dan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China; Hunan Clinical Research Center of Pediatr…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Quinolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax is a BCL2-targeted drug employed in treating various cancers, particularly hematologic malignancies. Venetoclax combination therapies are increasingly recognized as promising treatment strategies for acute myeloid leukemia (AML). In this study, we conducted an unbiased drug screen and identified anlotinib, a promising multi-targeted receptor tyrosine kinase inhibitor with oral activity currently utilized in the treatment of solid tumor, as a potent enhancer of venetoclax's anticancer activity in AML. Our investigation encompassed AML cell lines, primary cells, and mouse models, demonstrating effective low-dose combination therapy of anlotinib and venetoclax with minimal cytopenia or organ damage. Proteomic analysis revealed abnormal mitotic signals induced by this combination in AML cells. Mechanistically, anlotinib synergized with venetoclax by suppressing ARPP19 protein, leading to sustained activation of PP2A-B55δ. This inhibited AML cells from entering the mitotic phase, culminating in mitotic catastrophe and apoptosis. Additionally, we identified a specific synthetic lethal vulnerability in AML involving an ARPP19 mutation at S62 phosphorylation. These findings underscore the therapeutic potential of anlotinib and venetoclax combination therapy in AML, warranting further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesBridged Bicyclo Compounds, HeterocyclicQuinolinesMitosisIndolesDrug SynergismXenograft Model Antitumor AssaysApoptosisHumansAnimalsMiceCell Line, TumorAntineoplastic Combined Chemotherapy Protocols

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicQuinolinesIndolesanlotinib

Autor:innen und Institutionen

  • Department of Pediatrics, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China; Hunan Clinical Research Center of Pediatric Cancer, Changsha, 410013, Hunan, China.
  • Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
  • Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410031, Hunan, China. Electronic address: chenpan08@csu.edu.cn.
  • Department of Pediatrics, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China; Hunan Clinical Research Center of Pediatric Cancer, Changsha, 410013, Hunan, China. Electronic address: yangmin…

Zitieren

APA

Wang, D., He, J., Liu, S., Zhang, H., Tang, D., Chen, P., & Yang, M. (2024). Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216970

Vancouver

Wang D, He J, Liu S, Zhang H, Tang D, Chen P, et al. Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216970

BibTeX
@article{Wang2024,
  author = {Wang, Dan and He, Jing and Liu, Siyang and Zhang, Haixia and Tang, Daolin and Chen, Pan and Yang, Minghua},
  title = {Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.216970}
}
Kostenlos starten →